Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

Kenneth Rockwood; Dingwei Dai; Arnold Mitnitski

doi:10.1002/gps.1864

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

Kenneth Rockwood, Dingwei Dai, Arnold Mitnitski

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	207-214
Number of pages	8
Journal	International Journal of Geriatric Psychiatry
Volume	23
Issue number	2
DOIs	https://doi.org/10.1002/gps.1864
Publication status	Published - Feb 2008

ASJC Scopus Subject Areas

Geriatrics and Gerontology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/gps.1864

Cite this

@article{a4c85f2bc12e4da5ba677e2429564622,

title = "Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months",

author = "Kenneth Rockwood and Dingwei Dai and Arnold Mitnitski",

year = "2008",

month = feb,

doi = "10.1002/gps.1864",

language = "English",

volume = "23",

pages = "207--214",

journal = "International Journal of Geriatric Psychiatry",

issn = "0885-6230",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

AU - Rockwood, Kenneth

AU - Dai, Dingwei

AU - Mitnitski, Arnold

PY - 2008/2

Y1 - 2008/2

UR - http://www.scopus.com/inward/record.url?scp=39749116926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749116926&partnerID=8YFLogxK

U2 - 10.1002/gps.1864

DO - 10.1002/gps.1864

M3 - Article

C2 - 17621382

AN - SCOPUS:39749116926

SN - 0885-6230

VL - 23

SP - 207

EP - 214

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

IS - 2

ER -

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this